Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Alimera Sciences, Inc. ALIM NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
35/100
0/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$5.75
+3.8%

Alimera Sciences, Inc. (ALIM) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $5.54. It has a SharesGrow Score of 35/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is ALIM = $6 (+3.8% upside).

Financials: revenue is $81M, +19%/yr average growth. Net income is $20M (loss), growing at -102.4%/yr. Net profit margin is -24.9% (negative). Gross margin is 75.7% (-10.6 pp trend).

Balance sheet: total debt is $67M against $46M equity (Debt-to-Equity (D/E) ratio 1.46, moderate). Current ratio is 2.39 (strong liquidity). Debt-to-assets is 43.9%. Total assets: $154M.

Analyst outlook: 9 / 13 analysts rate ALIM as buy (69%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 48/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 35/100 (Fail), Future 55/100 (Partial), Income 10/100 (Fail).

$5.75
▲ 3.79% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Alimera Sciences, Inc., the average price target is $5.75, with a high forecast of $6.00, and a low forecast of $5.50.
Highest Price Target
$6.00
Average Price Target
$5.75
Lowest Price Target
$5.50

ALIM SharesGrow Score Overview

41/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 50/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ALIM

~
VALUE Partial
50/100
ALIM trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $6, implying +8.3% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
ALIM: +19%/yr revenue is, -102.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ALIM: Debt-to-Equity (D/E) ratio 1.46 (moderate), Current ratio is 2.39 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
35/100
ALIM: Gross margin is 75.7% (-10.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 9 / 13 analysts rate ALIM as buy (69%). Analyst consensus target is $6 (+8.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ALIM: Net profit margin is -24.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.606-5.65
Volume2.68M
Avg Volume (30D)866.83K
Market Cap$301.29M
Beta (1Y)1.25
Share Statistics
EPS (TTM)-0.79
Shares Outstanding$25.56M
IPO Date2019-11-04
Employees154
CEORichard S. Eiswirth Jr.
Financial Highlights & Ratios
Revenue (TTM)$80.75M
Gross Profit$61.17M
EBITDA$-1.12M
Net Income$-20.13M
Operating Income$-1.93M
Total Cash$12.09M
Total Debt$67.4M
Net Debt$55.31M
Total Assets$153.52M
Price / Earnings (P/E)-7
Price / Sales (P/S)3.73
Analyst Forecast
1Y Price Target$5.75
Target High$6.00
Target Low$5.50
Upside+3.8%
Rating ConsensusBuy
Analysts Covering13
Buy 69% Hold 31% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS0162592028

Price Chart

Track all markets on TradingView
ALIM
Alimera Sciences, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Drug Manufacturers - Specialty & Generic
2.61 52WK RANGE 5.65

People Also View

ORGO
ORGO
Organogenesis Holdings Inc.
$2.51
+5.46%
 LFCR
LFCR
Lifecore Biomedical, Inc.
$5.20
+5.26%
 DERM
DERM
Journey Medical Corporation
$5.26
+1.15%
 CYTH
CYTH
Cyclo Therapeutics, Inc.
$0.72
+0.00%
 ADMP
ADMP
Adamis Pharmaceuticals Corporation
$0.78
+0.85%
 MNK
MNK
Mallinckrodt plc
$0.34
-14.97%
 ATNX
ATNX
Athenex, Inc.
$0.20
+0.00%
 CPHI
CPHI
China Pharma Holdings, Inc.
$0.62
-4.97%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message